The standard of care for the first-line treatment of advanced NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations (about 80% of advanced NSCLC) remains a platinum-based doublet in patients with good performance status (PS) and no significant comorbidities. Here, ALK is linked to non-small cell lung carcinoma.